TransMedics Group (NASDAQ:TMDX) Shares Gap Up – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) gapped up before the market opened on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares trading hands.

Analyst Ratings Changes

A number of brokerages have commented on TMDX. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer reissued an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

The business has a 50 day moving average of $73.56 and a 200 day moving average of $120.20. The company has a market cap of $2.15 billion, a PE ratio of 68.11 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the business earned ($0.12) EPS. The business’s revenue was up 63.7% compared to the same quarter last year. As a group, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC increased its holdings in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Hood River Capital Management LLC bought a new position in shares of TransMedics Group during the second quarter valued at $18,854,000. Canada Pension Plan Investment Board bought a new position in shares of TransMedics Group during the second quarter valued at $16,086,000. Finally, Public Sector Pension Investment Board bought a new position in shares of TransMedics Group during the third quarter valued at $11,079,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.